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Abstract
Background: Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and
activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis.
Methods: Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD
Anderson Cancer Center starting in October 2008 were analyzed for PIK3CA, RAS (KRAS, NRAS), and BRAF mutations using
polymerase chain reaction-based DNA sequencing.
Results: PIK3CA mutations were found in 54 (11%) of 504 patients tested; KRAS in 69 (19%) of 367; NRAS in 19 (8%) of 225;
and BRAF in 31 (9%) of 361 patients. PIK3CA mutations were most frequent in squamous cervical (5/14, 36%), uterine (7/28,
25%), breast (6/29, 21%), and colorectal cancers (18/105, 17%); KRAS in pancreatic (5/9, 56%), colorectal (49/97, 51%), and
uterine cancers (3/20, 15%); NRAS in melanoma (12/40, 30%), and uterine cancer (2/11, 18%); BRAF in melanoma (23/52,
44%), and colorectal cancer (5/88, 6%). Regardless of histology, KRAS mutations were found in 38% of patients with PIK3CA
mutations compared to 16% of patients with wild-type (wt)PIK3CA (p=0.001). In total, RAS (KRAS, NRAS)o rBRAF mutations
were found in 47% of patients with PIK3CA mutations vs. 24% of patients wtPIK3CA (p=0.001). PIK3CA mutations were
found in 28% of patients with KRAS mutations compared to 10% with wtKRAS (p=0.001) and in 20% of patients with RAS
(KRAS, NRAS)o rBRAF mutations compared to 8% with wtRAS (KRAS, NRAS)o rw t BRAF (p=0.001).
Conclusions: PIK3CA, RAS (KRAS, NRAS), and BRAF mutations are frequent in diverse tumors. In a wide variety of tumors,
PIK3CA mutations coexist with RAS (KRAS, NRAS) and BRAF mutations.
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Introduction
Recently, major discoveries in the molecular biology of human
cancers along with an increased understanding of oncogenic
mutations and cell signaling pathways led to the successful
application of new targeted therapies in several cancers.[1,2,3,4]
These include the use of KIT kinase inhibitors in KIT-mutant
gastrointestinal stromal tumors (GIST), ABL kinase inhibitors in
BCR-ABL-positive chronic myelogenous leukemia (CML), EGFR
tyrosine kinase inhibitors in EGFR-mutant lung cancers, and
BRAF inhibitors in BRAF-mutant melanomas.[2,3,4,5] It appears
plausible that the most common cancers have been difficult to
treat, in part because they are heterogeneous, with each subset of
patients having different molecular abnormalities. Identifying
relevant molecular subtypes within heterogeneous cancers is
crucial to future targeted therapeutic progress.[6,7]
Key signals that are putatively activated in different tumor types
are in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR and
RAS/RAF/MEK signaling pathways, which regulate cell prolif-
eration and growth, apoptosis, autophagy, invasion, and migra-
tion.[8,9] Activation is frequently mediated by mutations in the
p110a subunit of PI3K, PIK3CA, with most mutations (.80%)
occurring either in exon 9, which codes for the helical domain, or
exon 20, which codes for the kinase domain.[8] Preclinical studies
suggested that PIK3CA mutations could predict response to PI3K
inhibitors, although concomitant mutations in RAS (KRAS, NRAS)
or BRAF might mediate resistance.[10]
Although several preclinical studies suggest that aberrations in
the PI3K/AKT/mTOR and the MAP kinase pathway may co-
exist, only limited studies in patients have been undertaken, and
have mostly concentrated on colorectal cancer.[8,10,11] We,
therefore, investigated the PIK3CA, RAS (KRAS and NRAS) and
BRAF mutation status of a large group of patients (N=504) with
advanced cancers referred to the Clinical Center for Targeted
Therapy (CCTT) at The University of Texas MD Anderson
Cancer Center (MD Anderson). We demonstrate that across
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mutations and RAS/BRAF mutations. These findings in the
clinical setting have important implications for the design of
clinical trials and treatments with PI3K/AKT/mTOR and BRAF
or MEK inhibitors.
Methods
Patients
We investigated the PIK3CA, RAS (KRAS, NRAS), BRAF
mutation status of patients with advanced tumors and available
tissue referred to the MD Anderson CCTT (phase I clinic) starting
in October 2008. The registration of patients in the database,
pathology assessment, and mutation analysis were performed at
MD Anderson. Eligible patients were those referred for phase I
clinical trials of targeted therapeutic agents who had a sufficient
amount of tumor tissue available for PIK3CA and, if possible, for
other mutation analyses. The study was conducted under the
umbrella of The IMPACT protocol, which was approved by The
University of Texas MD Anderson Cancer Center Institutional
Review Board I.
Tissue samples and mutation analyses
PIK3CA, RAS (KRAS, NRAS), BRAF mutations were investigated
in archival formalin-fixed, paraffin-embedded tissue blocks or
material from fine needle aspiration biopsy obtained from
diagnostic and/or therapeutic procedures. All histologies were
centrally reviewed at MD Anderson. Mutation testing was
performed in the Clinical Laboratory Improvement Amend-
ment–certified Molecular Diagnostic Laboratory within the
Division of Pathology and Laboratory Medicine at MD Anderson.
DNA was extracted from microdissected paraffin-embedded
tumor sections and analyzed using a polymerase chain reaction-
based DNA sequencing method for PIK3CA mutations in codons
[c]532–554 of exon 9 (helical domain) and c1011–1062 of exon 20
(kinase domain). This included the mutation hot spot region of the
PIK3CA proto-oncogene denoted by Sanger sequencing, following
amplification of 276 bp and 198 bp amplicons, respectively;
utilizing primers designed by the MD Anderson Molecular
Diagnostic Laboratory. Whenever possible, in addition to PIK3CA,
mutation analysis was done for KRAS and NRAS c12, c13, and c61
mutations of exons 1–2; and BRAF codon 595–600 mutations of
exon 15 by pyrosequencing as previously described.[12]
Statistical analysis
Fisher’s exact test was used to assess the association among
categorical variables and mutation status. All tests were two-sided,
and a P value less than 0.05 was considered statistically significant.
All statistical analyses were carried out using SPSS 17 computer
software (SPSS Chicago, IL).
Results
Patients
A total of 504 patients with diverse advanced cancers were
analyzed for the presence of PIK3CA mutations. Of these 504
patients, 367 (73%) patients were also tested for KRAS mutations,
225 (45%) for the presence of NRAS mutations, and 361 (72%) for
BRAF mutations. Two-hundred-and-ninety (58%) were women
and 214 (42%) were men. The median age was 57 years (range, 13
to 91 years). One-hundred-and-five (21%) patients had colorectal
cancers, 62 (12%) ovarian cancers, 55 (11%) melanomas, 34 (7%)
squamous cell cancers of head and neck, 29 (6%) breast cancers,
28 (6%) uterine cancers, 26 (5%) sarcomas, 22 (4%) non-small cell
lung cancers (NSCLC), 16 (3%) thyroid cancers, 15 (3%) non-
squamous cell cancers of head and neck, 14 (3%) squamous cell
cervical cancers, 12 (2%) adenocarcinomas of esophagus and
stomach, 11 (2%) pancreatic cancers, 8 (2%) cervical adenocar-
cinomas, 8 (2%) renal cancers and 59 (11%) had other tumor
types. Patient characteristics are listed in Table 1.
PIK3CA mutations
PIK3CA proto-oncogene mutations were detected in 54 (11%) of
the 504 patients. PIK3CA mutation status was not significantly
associated with age, gender, or race. In tumor types with more
than 10 patients tested, PIK3CA mutations were most common in
squamous cell cervical cancer, in 5 (36%) of 14 patients. Mutations
were also present in 7 (25%) of 28 patients with uterine cancer, 6
(21%) of 29 patients with breast cancer, 18 (17%) of 105 patients
with colorectal cancer, 5 (15%) of 34 patients with squamous cell
cancers of head and neck cancer, 7 (11%) of 62 patients with
ovarian cancer, 1 (9%) of 11 patients with pancreatic cancer, 1
(6%) of 16 patients with thyroid cancer, 1 (5%) of 22 patients with
NSCLC, and in 1 (2%) of 55 patients with melanoma (Figure 1A).
Among disease entities with more than 10 patients tested, no
PIK3CA mutations were found in sarcomas, and adenocarcinomas
of stomach and esophagus.
Mutations in exon 9 coding for the helical domain (E545K,
E542K, E545G, E545K/D549H, Q546K) were found in 28
patients. Exon 20 mutations coding for the kinase domain
(H1047R, H1047L, G1049R, M1043V, M1043I) were found in
26 patients. The most frequent mutations were H1047R (a
mutation in codon 1047 of PIK3CA that changes the encoded
amino acid from histidine to arginine) and E545K (a mutation in
codon 545 of PIK3CA that changes the encoded amino acid from
glutamic acid to lysine), each occurring in 16 (30%) of 54 patients
with PIK3CA mutations (Figure 2A). In tumor types with at least 5
PIK3CA mutations identified, analysis of frequency of mutations in
the helical vs. kinase domain was carried out. A predominance of
helical domain PIK3CA mutations was observed in patients with
cervical squamous (100% vs. 0%), colorectal (67% vs. 33%), and
squamous cell cancer of head and neck (60% vs. 40%), while
PIK3CA kinase domain mutations were predominant in patients
with uterine (86% vs. 14%), breast (83% vs. 17%), and ovarian
cancer (71% vs. 29%; p=0.002).
We analyzed frequencies of PIK3CA mutations in different
disease types in which specific mutations were identified in at least
5 tumor samples. In colorectal cancer, the most prevalent
mutation was E545K (8/18, 44%); in uterine cancer, H1047R
(4/7, 57%); in ovarian cancer, H1047R (3/7, 43%), in breast
cancer H1047R (4/6, 67%), in cervical cancer E545K (4/5, 80%),
and in squamous cell cancer of head and neck E542K (2/5, 40%).
The small number of patients in each subgroup precluded
performing a more detailed statistical analysis.
KRAS mutations
KRAS proto-oncogene mutations were detected in 69 (19%) of
367 patients tested.
In tumor types with more than 10 patients tested, KRAS
mutations were most frequent in colorectal cancer, in 49 (51%) of
97 tested patients. KRAS mutations were also present in 3 (15%) of
20 tested patients with uterine cancer, in 5 (11%) of 46 tested
patients with ovarian cancer, 2 (9%) of 22 assessed patients with
NSCLC, 1 (6%) of 17 tested patients with breast cancer, 1 (5%) of
22 tested patients with melanoma, and in 1 (4%) of 28 tested
patients with squamous cell cancer of head and neck (Figure 1B).
Among disease entities with more than 10 patients tested, no KRAS
mutations were found in sarcomas, and adenocarcinomas of
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cantly associated with age, gender, or race.
Mutations in c12 were found in 53 patients, c13 mutations in 10
patients, and c61 mutations in 6 patients. The most frequent
mutation was G12D (a mutation in codon 12 of KRAS that changes
the encoded amino acid from glycine to asparagine) detected in 21
patients (Figure 2B). We analyzed the frequencies of specific KRAS
mutations in different disease types, with mutations identified in at
least 5 tumor samples. In colorectal cancer, the most prevalent
mutation was G12D (15/49, 31%); in ovarian cancer Q61H (2/5,
40%), and in pancreatic cancer G12V (2/5, 40%) and G12R (2/5,
40%). The small patient numbers in each subgroup precluded
performing a more definitive statistical analysis.
NRAS mutations
NRAS proto-oncogene mutations were found in 19 (8%) of 225
patients analyzed. In tumor types with more than 10 patients
tested, NRAS mutations were most frequent in melanoma, in 12
(30%) of 40 tested patients. Mutations were also present in 2 (18%)
of 11 tested patients with uterine cancer and in 2 (6%) of 31 tested
patients with colorectal cancer (Figure 1C). Among disease entities
with more than 10 patients tested, no NRAS mutations were found
in ovarian cancer, and squamous cell carcinoma of head and neck.
NRAS mutation status was not significantly associated with age,
gender, or race.
Mutations in c61 were found in 18 patients, and 1 patient had a
c13 mutation. The most frequent mutation was Q61R (a mutation
in codon 61 of NRAS that changes the encoded amino acid from
glutamine to arginine) detected in 10 patients (Figure 2C).
BRAF mutations
BRAF proto-oncogene mutations were detected in 31 (9%) of
361 patients tested. In tumor types with more than 10 patients
tested, BRAF mutations were most frequent in melanoma, in 23
(44%) of 52 tested patients. Mutations were also present in 1 (8%)
of 12 tested patients with thyroid cancer, in 5 (6%) of 88 tested
patients with colorectal cancer, and in 2 (5%) of 43 tested patients
with ovarian cancer (Figure 1D). Among disease entities with more
than 10 patients tested, no BRAF mutations were found in
squamous cell cancers of head and neck, uterine cancers, breast
cancers, NSCLC, sarcomas, and adenocarcinomas of stomach and
esophagus. BRAF mutation status was not significantly associated
with age, gender, or race.
All mutations were in c600. The most frequent mutation was
V600E (a mutation in codon 600 of BRAF that changes the
encoding amino acid from valine to glutamic acid) in 26 patients
(Figure 2D).
Simultaneous PIK3CA and RAS (KRAS, NRAS) or BRAF
mutations
Either RAS (KRAS, NRAS)o rBRAF mutations were more
common in patients with mutant PIK3CA than in those with wild-
type (wt) PIK3CA (p=0.001) (Figure 3A). These mutations were
found in 24 (47%) of 51 patients with mutant PIK3CA, who were
also tested for RAS (KRAS, NRAS)o rBRAF mutations, but only in
94 (24%) of 385 patients with wtPIK3CA, who were also tested for
RAS (KRAS, NRAS)o rBRAF mutations (Table 2). Similar
associations between the proportion of RAS (KRAS, NRAS)o r
BRAF mutations in mutant PIK3CA and wtPIK3CA, although not
always statistically significant, were found in disease-specific
subanalysis in colorectal cancer (14/18 [78%] vs. 42/86 [49%];
p=0.04), ovarian cancer (5/7 [71%] vs. 2/43 [5%]; p,0.001),
and all tested cancers excluding colorectal (10/33 [30%] vs. 52/
299 [17%]; p=0.1) (Figure 3B–D).We also analyzed the frequency
of PIK3CA mutations in patients with mutant RAS (KRAS, NRAS)o r
BRAF compared to patients without RAS (KRAS, NRAS)o rBRAF
mutations. Patients with RAS (KRAS, NRAS)o rBRAF mutations
had a higher frequency of PIK3CA mutations (24 of 118 patients,
Table 1. Patient characteristics.
Characteristic Patients
N%
Sex
Male 214 42
Female 290 58
Age (years)
,50 142 28
50–70 298 59
.70 64 13
Ethnicity
Caucasian 401 79
African American 45 9
Hispanic 29 6
Asian 29 6
Tumor type
Colorectal 105 21
Ovarian 62 12
Melanoma 55 11
Head & neck: squamous 34 7
Head & neck: non-squamous 15 3
Breast 29 6
Uterine 28 6
Sarcomas 26 5
Cervix: squamous 14 3
Cervix: adenocarcinoma 8 2
Non-small cell lung 22 4
Small cell lung 2 ,1
Thyroid 16 3
Esophagus and stomach:
adenocarcinoma
12 2
Pancreatic 11 2
Renal 8 2
Neuroendocrine 7 1
Cholangiocarcinoma 5 1
Thymoma 5 1
Hepatocellular 5 1
Urothelial and bladder 5 1
Skin: non-melanoma 4 ,1
Vulvar 3 ,1
Adrenocortical 3 ,1
Mesothelioma 3 ,1
Carcinoma of unknown primary 3 ,1
Anal: squamous 2 ,1
Brain 2 ,1
Other 10 2
doi:10.1371/journal.pone.0022769.t001
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mutations. D. BRAF mutations.
doi:10.1371/journal.pone.0022769.g001
Figure 2. Proportion (numbers) of mutation types. A. PIK3CA mutations (n=54). B. KRAS mutations (n=69). C. NRAS mutations (n=19). D. BRAF
mutations (n=31).
doi:10.1371/journal.pone.0022769.g002
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mutations (27 of 318 patients, 8%; p=0.001).
When analyzing KRAS alone, these mutations were detected in
19 (38%) of 50 patients with PIK3CA mutations, who were also
tested for KRAS. In patients with wtPIK3CA, KRAS mutations were
found in 50 (16%) of 317 patients tested for both oncogenes
(Table 2). The difference was statistically significant (p=0.001)
(Figure 4A). Similar associations between the proportion of KRAS
mutations in patients with mutant PIK3CA and wtPIK3CA,
although not always statistically significant perhaps because of
smaller numbers of patients, were found in disease-specific
subanalysis in colorectal cancer (13/18 [72%] vs. 36/79 [46%];
p=0.07), ovarian cancer (4/7 [57%] vs. 1/39 [3%]; p=0.001),
and all tested cancers excluding colorectal (6/32 [19%] vs. 14/238
[6%]; p=0.02) (Figure 4B–D). We also analyzed the frequency of
PIK3CA mutations in patients with mutant KRAS vs. patients
wtKRAS. Patients with KRAS mutations had a higher frequency of
PIK3CA mutations compared to those wtKRAS (19/69 [28%] vs.
31/298 [10%]; p=0.001). Finally, we analyzed associations
between exon 9 PIK3CA and KRAS mutations and between exon
Figure 3. Simultaneous PIK3CA and RAS (KRAS, NRAS)o rBRAF mutations. Wild-type RAS (KRAS, NRAS)o rBRAF (blue bar) and mutant RAS
(KRAS, NRAS)o rBRAF (red bar) in: A. All tumor types (tested, n=436); B. All cancers excluding colorectal cancers (tested, n=332); C. Colorectal cancers
(tested, n=104); D. Ovarian cancers (tested, n=50).
doi:10.1371/journal.pone.0022769.g003
Table 2. PIK3CA, RAS (KRAS, NRAS), and BRAF mutations.
Oncogene Mutated (%) Total tested
PIK3CA 54 (11) 504
KRAS 69 (19) 367
NRAS 19 (8) 225
BRAF 31 (9) 361
KRAS in mutated PIK3CA 19 (38) 50
KRAS in wild-type PIK3CA 50 (16) 317
RAS/BRAF in mutated PIK3CA 24 (47) 51
RAS/BRAF in wild-type PIK3CA 94 (24) 385
doi:10.1371/journal.pone.0022769.t002
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strongly associated with KRAS mutations (12/62 [19%] in KRAS
mutant vs. 16/283 [6%] in wtKRAS; p=0.001), whereas the
association between exon 20 PIK3CA and KRAS mutations did not
reach statistical significance (7/57 [12%] in KRAS mutant vs. 15/
282 [5%] in wtKRAS; p=0.07). In addition, we analyzed
associations between exon 9 PIK3CA and KRAS mutations and
between exon 20 PIK3CA and KRAS mutations in colorectal and
ovarian cancers, which were the two largest disease subgroups. In
colorectal cancer, exon 9 PIK3CA mutations showed a trend
towards increased frequency in patients with KRAS mutations (9/
45; 20%) compared to patients with wtKRAS (3/46; 6%) (p=0.07),
whereas the frequency of exon 20 PIK3CA mutations did not
significantly differ (4/40 [10%] in KRAS mutant vs. 2/45 [4%] in
wtKRAS; p=0.4). In ovarian cancer, there was a strong association
between exon 20 PIK3CA and KRAS mutations (3/4 [75%] in
KRAS mutant vs. 2/40 [5%] in wtKRAS; p=0.003), while the
association between exon 9 PIK3CA and KRAS mutations did not
reach statistical significance (1/2 [50%] in KRAS mutant vs. 1/39
[3%] in wtKRAS; p=0.1). However, numbers of patients in these
subgroups were small, suggesting caution in interpreting these
results.
There was no significant difference in the prevalence of NRAS
mutations between wtPIK3CA and mutant PIK3CA groups,
however, the small number of patients tested in the mutant
PIK3CA group precluded drawing definite conclusions.
The proportion of BRAF mutations was similar (8–9%) in both
wtPIK3CA and mutant PIK3CA groups. Low patient numbers in
the mutant PIK3CA group made it problematic to arrive at
definitive conclusions.
Figure 4. Simultaneous PIK3CA and KRAS mutations. Wild-type KRAS (blue bar) and mutant KRAS (red bar) in: A. All tumor types (tested,
n=367); B. All cancers excluding colorectal cancers (tested, n=270); C. Colorectal cancers (tested, n=97); D. Ovarian cancers (tested, n=46).
doi:10.1371/journal.pone.0022769.g004
PIK3CA Mutations Coexist with RAS, BRAF Mutations
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22769Discussion
Across tumor types, we demonstrated a higher prevalence of RAS
(KRAS, NRAS)o rBRAF mutations (47%) and KRAS mutations (38%)
in patients with mutant PIK3CA compared to those with wtPIK3CA
(mutant RAS or BRAF present in 24%, p=0.001; mutant KRAS
present in 16%, p=0.001). Most previously published studies
investigating simultaneous PIK3CA, and RAS or BRAF mutations
concentrated on colorectal cancer.[11,13,14,15,16] Some studies
suggested that PIK3CA mutations are associated with KRAS
mutations,[11,13,15] whereas others did not report that.[16,17] A
large retrospective study that analyzed 1,022 tumor DNA samples
from patients with colorectal cancer treated with cetuximab in
multiple European institutions revealed association between exon 9
PIK3CA and KRAS mutations (14.7% in KRAS mutant vs. 6.8% in
wtKRAS; p=0.0006), but not between exon 20 PIK3CA and
KRAS mutations (3.8% in KRAS mutant vs. 2.3% in wtKRAS;
p=0.27).[11] In agreement with this paper, when we examined all
histologies, we also found a strong association between exon 9
PIK3CA and KRAS mutations (19% in KRAS mutant vs. 6% in
wtKRAS; p=0.001), however, the frequency of exon 20 PIK3CA
mutations also showed a trend towards being more common in
patients with KRAS mutations compared to wtKRAS (12% in KRAS
mutantvs. 5%inwtKRAS),albeitnot reachingstatistical significance
(p=0.07). In a disease-specific subanalysis in colorectal and ovarian
cancer we noticed a trend toward an association between exon 9
PIK3CA and KRAS mutations in colorectal cancer (20% in KRAS
mutant vs. 6% in wtKRAS; p=0.07) and a statistically significant
association between exon 20 PIK3CA and KRAS mutations in
ovarian cancer (75% in KRAS mutant vs. 5% in wtKRAS; p=0.003).
However, the numbers of patients are low in colorectal, and ovarian
cancer subgroup analyses suggesting that additional confirmatory
studies will be necessary.
An association between PIK3CA and RAS or BRAF mutations has
implications for cancer therapy. Preclinical models suggested that
cell line-derived xenografts with PIK3CA mutations are sensitive to
the PI3K inhibitor PX-866 unless they have RAS mutations.[10]
Nearly identical findings were reported from preclinical and early
clinical experiments with the mTOR inhibitor everolimus.[18]
Similar observations have been reported from early clinical
experiments when RAS or BRAF mutations in patients with mutant
PIK3CA were associated with resistance to PI3K/AKT/mTOR in
several cancers except for ovarian cancer.[19,20] These data
suggest that PIK3CA mutations might predict a response to PI3K/
AKT/mTOR pathway inhibitors in only a portion of patients. In
patients with simultaneous PIK3CA and RAS or BRAF mutations,
PI3K/AKT/mTOR inhibitionmightnot besufficientforachieving
a significant antitumor effect, and since RAS or BRAF mutations are
common in patients with mutant PIK3CA it is advisable to
determine the mutational status of RAS and BRAF in addition to
PIK3CA status. Of special interest, clinical trials combining MEK
and PI3K/AKT/mTOR inhibitors are in an early stage of clinical
development.[21] In addition, some preclinical experiments
suggested that PI3K inhibition might reduce the migration and
adhesion of tumor cells and consequently inhibit metastasis rather
than the primary tumor,whichmayhaveimportantimplicationsfor
treatment; however, these observations need to be confirmed in
additional experiments.[22,23]
In regard to individual aberrations, oncogenic mutations in two
hot spot regions (exons 9 and 20) of PIK3CA have been identified
in various malignancies, including common tumors such as breast,
lung, colorectal, ovarian and uterine.[11,24,25,26,27,28,29] In
this study, PIK3CA mutations were identified in 11% of diverse
tumor types. Tumors with a high prevalence of PIK3CA mutations
were squamous cell cervical (36%), uterine (25%), breast (21%),
colorectal (17%), squamous cell head and neck (15%), and ovarian
cancers (11%). These data are similar to those previously
published except for cervical cancer, which was shown to have a
prevalence of PIK3CA mutations ranging from 8% (8/98) in
the COSMIC database to 16% (2/12) published by Miyake
et al.[29,30] Colorectal and squamous cervical cancers were found
to have a predominant E545K (exon 9) mutation (44%, 80%,
respectively); uterine, ovarian, and breast cancers, a predominant
H1047R (exon 20) mutation (57%, 43%, 67%, respectively); and
squamous cell cancers of head and neck, an E542K (exon 9)
mutation (40%). These differences may have clinical significance
as some preclinical data generated a hypothesis that when exon 20
mutations are present in the kinase domain, they might be more
sensitive to PI3K/AKT/mTOR inhibitors than exon 9 mutations
in the helical domain.[18]
KRAS mutations occur in different tumor types, and are
particularly important in colorectal, pancreatic, and NSCLC
carcinogenesis.[11,31,32,33,34] KRAS mutations predict a lack of
therapeutic benefit of anti-EGFR monoclonal antibodies in
colorectal but, not convincingly, in lung cancer.[35,36,37]
Functional RAS may also be potentially important for regulating
the actin cytoskeleton, which was suggested as being a critical
driver of oncogenic transformation.[38] In our study, a high
prevalence of KRAS mutations was found in pancreatic (56%),
colorectal (51%), uterine (15%), and ovarian (11%) cancers, which
is similar to previously published findings and data from the
COSMIC database.[11,29] Colorectal cancers were found to have
a predominant G12D mutation (31%); pancreatic cancers, G12V
and G12R mutations (40% each); and ovarian cancers, Q61H
mutations (40%). These distinctions may be clinically important as
some preclinical data suggest that different mutations might
activate different pathways. Ihle et al.[39] demonstrated that a
G12D mutation activates both PI3K/AKT/mTOR and MAPK
pathways, whereas a G12C mutation causes robust RAL signaling.
NRAS mutations have been mainly described in melanomas and
leukemias and their prognostic significance has been unclear, with
some data suggesting an association between mutant NRAS and a
worse prognosis in melanoma.[40,41,42] In our study, there was a
high prevalence of NRAS mutations in melanoma (44%), and
uterine cancer (15%). The prevalence of NRAS mutations was
higher than reported in other studies or in the COSMIC database
(14–20%).[29,43]
BRAF mutations have been mainly reported in melanoma,
colorectal, papillary thyroid, and ovarian cancer.[44,45] In
colorectal cancer they are associated with a dismal prognosis,
however, unlike KRAS mutations, BRAF mutations might not be
predictive of lack of cetuximab benefit.[46] In melanoma, the
prognostic significance of BRAF mutations is less obvious, although
patients with BRAF mutant melanoma seem to respond very well
to BRAF inhibitors.[4,42,47] In papillary thyroid cancer, BRAF
mutations were found to upregulate microenviromental genes,
which potentially increases tumor aggressiveness.[48] In agree-
ment with previously published data, our study showed a high
prevalence of BRAF mutations in melanoma (44%) and, to much
lesser extent, in thyroid, colorectal, and ovarian cancer (8%, 6%,
and 5%, respectively). Although the prevalence of BRAF mutations
in thyroid cancer was much lower than the 51% previously
published, this discrepancy could be explained by the presence of
histologies other then papillary.[49]
In conclusion, we studied the prevalence of PIK3CA, RAS (KRAS,
NRAS), and BRAF mutations in diverse tumor samples and
identified a high frequency of coexisting PIK3CA and BRAF or RAS
mutations. Simultaneous activation of PI3K/AKT/mTOR and
PIK3CA Mutations Coexist with RAS, BRAF Mutations
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22769RAS/RAF/MEK pathways can be associated with resistance to
PI3K/AKT/mTOR inhibitors.[10,18] These results are particu-
larly important because of the many PI3K/AKT/mTOR and
RAS/RAF/MEK targeting agents currently undergoing clinical
testing and suggest that molecular profiling and matching patients
with combinations of these targeted drugs will need to be
investigated in depth.
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